DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

DE

447.26

-4.91%↓

FDX

215.59

-12.15%↓

PAYX

153.66

-0.92%↓

CPRT

56.65

-1.58%↓

HEICA

203.75

-4.28%↓

Search

India Globalization Capital Inc

Cerrado

0.27 -3.57

Resumen

Variación precio

24h

Actual

Mínimo

0.27

Máximo

0.28

Métricas clave

By Trading Economics

Ingresos

-112K

-1.8M

Ventas

-155K

257K

Margen de beneficios

-711.673

Empleados

67

EBITDA

-263K

-1.9M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+1417.86% upside

Dividendos

By Dow Jones

Próximas Ganancias

20 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

23M

Apertura anterior

3.84

Cierre anterior

0.27

India Globalization Capital Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 sept 2024, 04:00 UTC

Principales Noticias

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

Comparación entre iguales

Cambio de precio

India Globalization Capital Inc previsión

Precio Objetivo

By TipRanks

1417.86% repunte

Estimación a 12 Meses

Media 4.25 USD  1417.86%

Máximo 4.25 USD

Mínimo 4.25 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para India Globalization Capital Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de India Globalization Capital Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.